Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Satralizumab - Chugai Pharmaceuticals/Roche

Next Previous
X
Search
Drug Profile

Satralizumab - Chugai Pharmaceuticals/Roche

Alternative Names: ENSPRYNG; RG-6168; SA-237; Satralizumab-mwge

Latest Information Update: 25 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuromyelitis optica
  • Phase III Encephalitis; Graves ophthalmopathy
  • Phase II Duchenne muscular dystrophy
  • No development reported Rheumatoid arthritis
  • Discontinued Myasthenia gravis

Most Recent Events

  • 23 Oct 2024 Phase-II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in Poland (SC) (NCT06450639)
  • 23 Oct 2024 Phase-II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in USA (SC) (NCT06450639)
  • 10 Jun 2024 Hoffmann-La Roche plans to initiate a phase II (SHIELD DMD) trial for Duchenne Muscular Dystrophy (In children, In Adolescents) in the US (SC) (NCT06450639)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top